Jasper Therapeutics, Inc.
JSPR
$0.72
$0.022.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 65.06% | 29.26% | -6.36% | -43.27% | -45.62% |
| Total Depreciation and Amortization | -57.60% | -41.50% | -23.09% | -28.35% | 15.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -291.77% | -208.94% | -64.74% | 26.89% | 57.87% |
| Change in Net Operating Assets | -268.74% | -4,439.50% | -2,775.54% | 371.46% | 6,473.73% |
| Cash from Operations | 17.89% | 1.21% | -23.26% | -31.89% | -31.51% |
| Capital Expenditure | 100.00% | 98.67% | 98.73% | 84.99% | 8.50% |
| Sale of Property, Plant, and Equipment | 150.00% | -66.67% | -40.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 123.19% | 100.20% | 100.94% | 89.65% | 16.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 335.74% | 6,358.13% | -27.84% | -26.64% | -86.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 330.52% | 6,294.58% | -28.55% | -26.17% | -86.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.17% | 50.26% | -181.61% | -266.06% | -648.46% |